Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allarity Therapeutics (ALLR) Cash from Financing Activities (2024 - 2025)

Allarity Therapeutics' Cash from Financing Activities history spans 2 years, with the latest figure at -$240000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 105.67% year-over-year to -$240000.0; the TTM value through Dec 2025 reached $10.6 million, down 71.06%, while the annual FY2025 figure was $10.6 million, 71.06% down from the prior year.
  • Cash from Financing Activities reached -$240000.0 in Q4 2025 per ALLR's latest filing, down from $2.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $26.3 million in Q2 2024 to a low of -$2.6 million in Q2 2025.